Skip to main content

Clinical Trials for Transitional Cell Cancer of the Renal Pelvis and Ureter

Trials 26-33 of 33

Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Neoadjuvant Immunotherapy (Atezolizumab and Tiragolumab) for the Treatment of Cisplatin-Ineligible Resectable High-Risk, Muscle-Invasive Urothelial Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
ALG.APV-527 First-in-human Study
Status: Active
Location: Icahn School of Medicine at Mount Sinai, New York, New York
A Personalized Cancer Vaccine for the Treatment of Muscle-invasive Bladder Cancer in Patients with Molecular Residual Disease
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Status: Active
Location: 2 locations
Tesetaxel for Previously Treated Patients With Bladder Cancer
Status: Active
Location: See ClinicalTrials.gov
A Study of DF6002 Alone and in Combination With Nivolumab
Status: Active
Location: See ClinicalTrials.gov
N-803 in Combination with Pembrolizumab and Enfortumab Vedotin for the Treatment of Locally Advanced and Metastatic Urothelial Cancer
Status: Approved
Location: University of California San Francisco, San Francisco, California